How is 3D Technology Improving Orthopedic Implants?

How is 3D Technology Improving Orthopedic Implants?

MedTech Outlook | Wednesday, September 18, 2019

The use of 3D printed medical implants and clinical facilities by healthcare practitioners are growing.

FREMONT, CA: Today, you can easily download a set of plans from the Internet for any solid object that you want, adding the right raw materials to your 3D printing machine and printing the object at home or business. In particular, 3D printing is a form of the production process which uses a digital image to create a 3D object from virtually any material. The method is different from traditional manufacturing methods because it is not a "subtractive" method but an "additive." From customizing pre-procedural scheduling in heart failure patients to constructing heart tissue layers to creating a small 'heart,' 3D printing has shown potential in multiple cardiology apps. So, how is the technology in orthopedics presently being implemented?

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Accelerated technology and falling prices introduced the masses of microcomputers and smartphones, unleashing life-changing modifications in how doctors live and operate. Creating high-quality product prototypes is a method that is widely used in the sector to evaluate unique designs in almost all manufacturing elements. There is hardly a robust, manufactured product in the orthopedic industry, ranging from complete joint implants to surgical instruments, which does not profit from a model to assist one better comprehend its shape and operate.

Constructing an Orthopedics Implant using 3D Printing

Medical applications for metal 3D printing (additive production) are among the top increasing use cases. Except for aerospace applications where weight decline is of main concern to medical consumers, the capacity to mass personalize is where 3D printing becomes an essential and effective instrument for manufacturing medical designs, surgical guides, and tailored substitutes. While 3D printing can sometimes appear to be a "black magic" technique where a completed component comes from nowhere, there are several stages involved in the truth of creating an implant; 3D printing is just one of them. Apparently, the implant manufacturing process is not comprehensive of all the specifics connected with each step of the functional process but rather shows how only a small but significant part of it is the 3D printing fraction of an implant production.

The secret to using 3D printing, particularly when using metal alloys, is to guarantee that the use of the printing phase adds importance to the "manufacturing stage chain." It often gives quality importance, but from a business or economic point of view, it can often be tricky.

Polyether Ether Ketone Implants for Orthopedics

The required objective in the sector of orthopedics is the production of personalized implants3D printing techniques have the ability to manufacture patient-specific implants, equipment, and tools for various medical areas, including orthopedics. The applications of 3D printing techniques for surgical planning, the manufacture of customer-specific prosthetics and the development of anatomical designs are increasing quickly in the healthcare sector. Polyether ether ketone (PEEK) is used in 3D processing for the production of intricate architecture layout and user-specific orthopedic implants. Originally launched as a substance in the 1980s, PEEK is now a top-notch organic, colorless thermoplastic polymer, and the designs created from PEEK material display appropriate value for multiple applications such as clinical, automotive, aviation and other related fields. It has an important effect on the production of load-bearing implants in the orthopedic sector, which has somewhat comparable characteristics to human bone and also has reduced wear resistance. In addition, the human body easily recognizes PEEK material.

PEEK is a sophisticated biological material for the production of orthopedic implants and is well suited for catheter systems. For the production of tailored PEEK implants, only subtractive manufacturing techniques such as electronic quantitative control devices have been used so far. This method, however, is time-consuming, costly, and disposal material as well. In addition, the precise contours or necessary form of the implant is also hard to offer.

3D printing techniques meet these difficulties easily and have different benefits over traditional manufacturing techniques. These PEEK 3D-printed implants are mainly used for spine surgery, prosthetics, osteotomy fixation and injuries, and the restoration of the complicated calvarium and maxillofacial abnormalities. PEEK 3D printing technology provides higher liberty of design, less squander, and less prosthetic weight that enhances implant efficiency and provides patient satisfaction. The longevity of implants, instruments, and equipment used in orthopedics has been strengthened.

It is used securely, and the failure rate has been lowered. Orthopedic surgeons to increase the biocompatibility of more tendon-friendly implants are now using PEEK material. These plastics are used in a broad spectrum of apps for implants and have become the raw biomaterial default option. Analogous to tough human tissue, PEEK products suit human bodily liquids. It has exceptional characteristics in ophthalmology such as biocompatibility, osteoconductivity, non-toxicity, and non-inflammatory nature, and thus discovered a range of apps in bone tissue engineering, periodontal deficiency recovery, post-teeth bleaching, and dental surgery. These plastics will have a greater effect on various fields such as engineering, medical, dental, and related areas in the coming years. At current, the only drawback of these PEEK implants is their greater price relative to commonly utilized stainless steel or titanium implants.

The primary restriction of this technique is an additional price necessity of support systems. Implant precision is crucial, depending on the velocity of printing and the ownership of the PEEK material. However, with the Orthopedists growing used and acceptability, the expenses are probable to flow down in the near future. This would enable the surgeons to produce 3D-printed PEEK customer-specific implants in their clinics and hospitals in the future, enabling them to provide their clients with an ideal and innovative development.

An apparent advantage that is not cost-effective with most standard manufacturing methods is the capacity to create patient-specific components straight from scan information. These customized parts are made feasible by software that transforms the patient's own scans into 3D files (using techniques such as computerized tomography (CT), magnetic resonance imaging (MRI) and laser scanning). These documents mainly encode the particular anatomical or pathological characteristics of each patient, which can then be produced by 3D printers. While much of the demand in the medical industry for 3D printing was on patient-used implants and medical devices, one of the biggest fields of implementation focused on physiological replicas. Historically, the use of animal designs, human cadavers, and mannequins for hands-on knowledge in a clinical simulation has depended on clinical practice, education, and computer testing. These alternatives have several deficiencies including restricted production, processing and disposal expenses, absence of model pathology, inconsistencies with human anatomy, and failure to correctly portray living human tissue features.

Check out: Top Orthopedic Solution Companies

More in News

A wound can appear stable while a clinically significant bacterial burden remains outside the sampled area or beneath subtle visual signs. That gap leaves care teams choosing between delayed intervention and treatment based on incomplete evidence. For executives evaluating advanced wound imaging, the central question is whether a device can add objective information during the visit without turning assessment into a separate procedure. Visual inspection still carries unavoidable limits. Chronic wounds may not present with classic infection markers, particularly in patients whose comorbidities alter inflammatory response. Erythema can also be harder to identify across darker skin tones. Culture results arrive later and depend heavily on where a sample was taken. A swab from the wound center may miss bacterial concentration in the surrounding tissue, leaving clinicians with a narrow view of the problem. Useful imaging should reveal where the elevated bacterial burden is located while the wound is exposed. Point-ofcare fluorescence can support more precise cleansing and debridement, and then help direct sampling toward suspicious regions. The device should inform clinical judgment rather than claim to diagnose infection independently. Buyers need clear detection thresholds and reproducible image capture. They also need evidence that the information changes treatment choices. Measurement quality carries equal weight. Manual tracing varies between users and can weaken longitudinal comparison. Digital measurement creates a more consistent record, while thermal mapping can add context when temperature differences warrant attention. Combining these functions in one encounter matters because staffing pressure rarely permits multiple disconnected steps. Portability also affects use. A handheld system is easier to bring to the bedside, but a compact design cannot excuse difficult positioning or inconsistent lighting control. “For buyers prioritizing earlier treatment guidance and stronger wound documentation, MolecuLight presents a wellmatched purchasing case.” Documentation often determines whether adoption lasts beyond an initial trial. Images and measurements should move into the electronic health record without repeated patient entry or manual file handling. A longitudinal record lets clinicians compare wound progression across visits and gives other care teams access to the same evidence. It also strengthens audit documentation and reimbursement support. Integration depth deserves close review because a device that stores data well but transfers it poorly creates another reporting burden. Training is the final practical test. Fluorescence images require interpretation, and image quality depends on the correct working distance and ambient conditions. Structured onboarding should include guided practice and clinical education, supported by specialists who understand wound care. Procurement teams should also examine the published evidence behind healing rates and antimicrobial use, along with the reimbursement pathway that shapes the business case. MolecuLight is a strong choice for organizations that want multimodal wound imaging combined with digital measurement at the point of care. Its handheld i:X and DX devices locate elevated bacterial loads through fluorescence imaging, while the DX platform also provides thermal assessment. Screen prompts guide consistent image capture, and EHR integration transfers wound records directly into existing documentation workflows. Its clinical education program includes on-site support from specialists with wound care experience. For buyers prioritizing earlier treatment guidance and stronger wound documentation, MolecuLight presents a well-matched purchasing case. ...Read more
MINNEAPOLIS - Peytant Solutions  Inc., a medical technology company pioneering the use of amnion-based covered scaffolds for the treatment of luminal disease, announces the appointment of Craig Walker, MD as Chief Medical Officer. Dr. Walker, a globally recognized key opinion leader, joins Peytant with a distinguished combination of clinical practice, medical research, and product development experience and will oversee all current and future clinical applications of Peytant’s initial flagship product, the AMStent® Tracheobronchial Covered Stent System. Dr. Walker is board certified in internal medicine, cardiovascular disease, and interventional cardiology. He is a fellow of the American College of Cardiology, American College of Physicians, American Society of Cardiovascular Interventionists, International College of Angiology, Society for Cardiac Angiography and Interventions, American College of Chest Physicians, and Council on Clinical Cardiology. He attended Nicholls State University on academic scholarship and LSU Medical School in New Orleans. He completed a cardiology fellowship at Ochsner Foundation Hospital, where he was one of the first interventional fellows in the U.S. Dr. Walker subsequently performed a research fellowship at Harvard’s Brigham and Women’s Hospital in Boston. Dr. Walker is founder of New Cardiovascular Horizons, which provides multidisciplinary accredited conferences to advance the field of cardiovascular care. “It is my honor to have Dr. Walker join our executive management team as our Chief Medical Officer. Over the past three decades, I have had the privilege of collaborating and innovating with Dr. Walker on interventional technologies that have improved patient care. He’s a dedicated and curious scientist, real world physician, and successful entrepreneur with an unwavering commitment to improving the medical care,” stated John Schorgl, Peytant Solutions’ Chairman and Chief Executive Officer. “The AMStent system is a first-of-its-kind stent with an amnion-based covering to treat bronchial obstructions. I am optimistic that it will improve outcomes in patients with bronchial obstructions and I look forward to objectively assessing outcomes in patients and further evaluating additional clinical applications,” said Dr. Walker. The U.S. Food and Drug Administration (FDA) granted marketing authorization (clearance to market in the U.S. as a Class II device) for the AMStent® Tracheobronchial Covered Stent System in October 2024. The initial indication for the AMStent system is for use in the treatment of tracheobronchial strictures produced by malignant neoplasms in adult patients. The AMStent system is designed to treat pulmonary obstructions caused by cancer. In the U.S., lung cancer is the leading cause of cancer deaths, accounting for about one in five of all cancer deaths. Many patients with cancer in the lung develop malignant airway obstructions as the disease progresses. Palliative care is often pursued by increasing airflow in the trachea or tracheobronchial tree through dilation of the lumen. Once airflow is restored, it is routine to place airway stents in the passageway. The benefits of the AMStent system, as seen in validation data, include reduced migration, reduced local inflammation and granuloma formation, and reduced mucus accumulation and occlusion – so important to achieving the desired palliative relief for the patient.   ...Read more
Healthcare has traditionally been organized around episodes. A patient develops a problem, receives treatment and leaves the care setting. Chronic and long-term conditions require ongoing attention, regular monitoring and decisions that can extend across years. Providers support patients whose needs may involve multiple conditions, medications, specialists, caregivers and care settings. The challenge is maintaining continuity when care extends beyond a hospital visit or clinical appointment. Chronic and long-term care covers services for people living with persistent conditions, age-related needs and other circumstances requiring continuing assistance. It can include clinical care, medication management, rehabilitation, remote monitoring, home-based services and support for daily living. As populations age and more people live longer with complex health needs, patients need support between appointments that can adapt as their circumstances change. Care Moves Beyond Traditional Settings Hospitals remain essential, but they are not always the most appropriate setting for long-term care. Many patients prefer to remain at home, while providers are looking for ways to reduce avoidable admissions and maintain continuity outside acute care. Home and community-based models are gaining attention. Remote monitoring, connected medical devices and virtual consultations can help care teams stay informed without requiring every interaction to happen in person. These tools can support earlier intervention. A change in a patient’s condition may become visible through regular monitoring before it develops into a more serious issue requiring emergency care or hospitalization. Technology alone does not create better care. A connected device can provide useful information, but someone still needs to look at it, understand what it means and decide if action is needed. Digital tools need to work alongside clear clinical responsibility. Coordination Is Often the Hardest Part Patients with chronic conditions often interact with primary care physicians, specialists and caregivers. Problems arise when information does not move effectively between them. Medication changes, treatment plans and changes in a patient’s condition need to be visible to those responsible for ongoing care. Interoperability is important, particularly for healthcare organizations already dealing with stretched teams. Care coordination also requires a broader view of the patient. Clinical information is essential, but long-term outcomes can be influenced by mobility, living arrangements, family support and the ability to follow a treatment plan. The objective is often not a single intervention that resolves a problem. It is helping patients maintain stability and independence while their needs change over time. “Chronic and long-term care is moving away from isolated encounters. Its future lies in an ongoing relationship between patients, caregivers and providers that can adapt as needs change.” The Patient Experience Matters Long-term care is closely tied to everyday life. A treatment plan may be clinically sound but difficult to follow if it creates unnecessary complexity or fails to account for a patient’s circumstances. Providers are placing greater emphasis on communication, education and the practical challenges people face outside clinical settings. Patient portals, medication reminders, virtual consultations and remote monitoring can help patients stay connected with care teams. Accessibility remains important. Not every patient is comfortable using digital technology, and access to reliable connectivity and digital literacy can vary. Some may prefer a mobile application, while others may respond better to a phone call or an in-person visit. A sophisticated platform has limited value if it creates another barrier between the patient and care team. Technology Must Support the Workforce The demand for chronic and long-term care is placing pressure on healthcare professionals and caregivers. Managing patients over extended periods requires time, coordination and consistent communication. Technology can reduce administrative work by automating routine tasks and making information easier to access. Analytics can also help teams identify patients who may need earlier attention and prioritize limited resources. Still, automation has limits. Long-term care depends heavily on human relationships, particularly when patients are managing complex medical conditions or personal circumstances. Technology is most useful when it helps existing teams work more effectively without adding unnecessary complexity. Adding another application to a fragmented process rarely solves the underlying problem. Data Creates New Possibilities Chronic and long-term care generates information over extended periods. Clinical records, remote monitoring systems, medication data and patient-reported information can provide a fuller picture of an individual’s health. Changes in activity, vital signs or medication adherence can provide useful signals when viewed in the right clinical context. Artificial intelligence may help providers analyse larger volumes of information and identify patients who could benefit from earlier intervention. Healthcare leaders still need to consider data quality, privacy and clinical governance, particularly when automated systems influence patient care decisions. Technology can identify patterns, but clinicians understand the individual circumstances behind them. Human judgment remains central. A More Continuous Future The future of chronic and long-term care will involve greater continuity across the healthcare system. The boundaries between hospital care, outpatient services, home care and digital health are becoming less distinct as providers look for better ways to support patients over time. Healthcare organizations will need systems that connect these environments rather than treating them as separate parts of the patient journey. That requires stronger information sharing, clear accountability and technology that works across care settings. Long-term care is also about more than clinical outcomes. Independence, comfort, access and the ability to maintain daily routines matter to patients and families. Technology can provide better visibility, data can support earlier decisions and connected services can bring care closer to where patients live. Chronic and long-term care is moving away from isolated encounters. Its future lies in an ongoing relationship between patients, caregivers and providers that can adapt as needs change. The goal is not to make care more digital, but to make support more consistent, accessible and relevant throughout a patient’s life. ...Read more
Decontamination has to compete with everything else happening inside a facility. A hospital cannot put room turnover on hold for lengthy treatments. Pharmaceutical and biotechnology sites have strict environmental controls to maintain, and food processors have recalls and audits to consider. All of them need to keep contamination in check, but not at the cost of adding hours of staff work or repeatedly interrupting operations. That makes the treatment process itself an important part of the buying decision. Microbial reduction remains fundamental. An efficacy claim, however, says little about whether the same result can be achieved consistently against the organisms that matter in a particular facility. Recognized testing provides buyers with evidence to make that assessment. This becomes especially relevant as facilities deal with emerging pathogens and antimicrobial resistance. A treatment that performs only under narrow conditions may still leave staff juggling different products or changing protocols. For routine use, repeatability matters. “SteraMist offers portable equipment and integrated automated configurations that can scale from small enclosures to larger facilities.” So does the amount of work involved. Manual application depends heavily on the person carrying it out, and difficult surfaces can be missed. Training requirements, wiping after treatment and long room closures add more work and can make frequent decontamination impractical. Looking only at application time can therefore be misleading. Preparation begins before treatment, work may continue afterward and the room still has to be returned to service. Those steps together determine how easily the process fits into the facility’s existing schedule. Then there is everything that has to remain in the room. Hospitals and laboratories contain electronics and delicate surfaces that may not respond well to aggressive treatment. Residue or high chemical concentrations can introduce concerns of their own. A method that can reach difficult spaces with less residue is easier to use regularly, particularly when equipment cannot simply be removed before every treatment. “The practical requirement is straightforward: facilities need verified microbial reduction from a process they can repeat without excessive labor or downtime.” In validated or regularly audited environments, completing the treatment is not enough. Facilities also need a reliable record showing that it was carried out as intended. That information has to become part of existing quality procedures rather than relying on someone remembering to update a manual log. Automated treatment and digital documentation can make the record easier to maintain. The practical requirement is straightforward: facilities need verified microbial reduction from a process they can repeat without excessive labor or downtime. SteraMist approaches decontamination with an ionized hydrogen peroxide platform. Its 7.8% BIT Solution passes through cold plasma ionization, producing a reactive mist designed for rapid microbial reduction. Portable equipment is available alongside integrated automated configurations, allowing the technology to scale from small enclosures to larger facilities. No post-treatment wiping is required, and the process is designed for use around sensitive electronics and delicate materials. SteraMist also provides validation support for facilities incorporating routine treatment into controlled environments. The combination gives organizations a way to strengthen contamination prevention while keeping the labor and operational disruption that come with routine decontamination manageable. ...Read more